CARsgen Therapeutics Holdings Ltd. has announced that the abstract of their research results on SATRI-CEL for adjuvant therapy of pancreatic cancer has been accepted for poster presentation at the ESMO Congress 2025. The study focuses on the application of SATRI-CEL, a CAR T-cell therapy, aimed at targeting solid tumors such as pancreatic cancer. The presentation is scheduled for a future date, as part of CARsgen's ongoing efforts to advance their product pipeline addressing challenges faced by existing CAR T-cell therapies, including improving safety, enhancing efficacy, and reducing treatment costs.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。